The rationale for development of ligelizumab in food allergy

Robert A. Wood MD⁎, R. Sharon Chinthrajah MDb, Alexander Eggel PhDc,d, Ivan Bottoli MDe, Aurelie Gautier MSc, Maximilian Woisetschlaeger PhD, Paolo Tassinari MSc and Pablo Altman MDf

ABSTRACT

Food allergy (FA) is a growing healthcare problem worldwide and the rising prevalence in many countries can be attributed to lifestyle, environmental, and nutritional changes. Immunoglobulin E (IgE)-mediated FA is the most common form of FA affecting approximately 3%–10% of adults and 8% of children across the globe. Food allergen-induced immediate hypersensitivity reactions mediated by IgE and high-affinity IgE receptor (FcεRI) complexes on mast cells and basophils are a major hallmark of the disease. FA can affect several aspects of health-related quality of life and impose a substantial financial burden on patients and healthcare systems. Although currently there is one United States Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved treatment for peanut allergy (Palforzia), the main treatment approaches are based on allergen avoidance and symptom management. Thus, there is an urgent need for more effective and ideally disease-modifying strategies. Given the crucial role of IgE in FA, anti-IgE monoclonal antibodies are considered promising therapeutic agents. Talizumab was the first humanized anti-IgE antibody to demonstrate substantial protection against allergic reactions from accidental peanut exposure by substantially increasing the peanut reactivity threshold on oral food challenge. However, development of talizumab was discontinued and further trials were performed using omalizumab. In double-blind, Phase 2, placebo-controlled trials in patients with multi-FAs, sustained dosing with omalizumab, or omalizumab in combination with oral immunotherapy, enabled rapid desensitization to multiple trigger foods. In this review, we describe the development of ligelizumab (a derivative of talizumab), a next generation, humanized monoclonal anti-IgE antibody, its existing clinical evidence, and its potential in the management of FA. When compared with omalizumab, ligelizumab binds with ~88-fold higher affinity for human IgE and recognizes a different epitope that substantially overlaps with the binding site of FcεRI. These properties translate into a high potency to block IgE/FcεRI signaling in both in vitro and in vivo studies. Given its efficient suppression of IgE levels, good safety and pharmacokinetic/pharmacodynamic profile, ligelizumab clearly warrants further studies for the potential management of FA.

Keywords: Food allergy, IgE, Ligelizumab, Omalizumab, Talizumab
INTRODUCTION

Food allergy (FA) refers to the reproducible adverse immune response to antigens delivered orally and is characterized by the breakdown of mucosal immune tolerance against certain ingested foods (eg, milk, egg, peanut).[^1][^2] The prevalence of FA has been rapidly and increasing in children over the past couple of decades, and although data regarding changes in the prevalence in adults are more limited, FA is common at all ages.[^3] Indeed, an increased incidence of new-onset FA has been reported in adults, with wheat, shellfish, soy, tree nut, and fin fish FAs being the most common adult-onset FAs.[^4] A rapidly rising prevalence of FA in many countries (eg, United States, United Kingdom, Australia, China, and Taiwan) suggests that it is an emerging health priority, particularly in the more economically developed countries.[^5][^6][^7]

Compared with other classic allergic conditions such as allergic rhinitis, allergic asthma, atopic dermatitis, and non-classic conditions such as nasal polyposis and chronic spontaneous urticaria (CSU), FA seems to have a stronger association with immunoglobulin E (IgE)-mediated pathology.[^8][^9] IgE-mediated FAs are characterized by type I hypersensitivity reactions.[^10] The IgE-driven mechanism is the most common cause of clinical conditions summarized under the term “food allergy” and is different from nonimmunogenic food intolerance (such as lactose intolerance), food poisoning, or pharmacological responses to food components (such as caffeine and glutamates).[^11][^12][^13] IgE-mediated FA affects an estimated 3%-10% of adults and 8% of children worldwide.[^14] Symptoms can range from mild to severe and can involve multiple organ systems.[^10] Aside from the risk of severe and even fatal consequences of FA, there is considerable evidence that FA poses a strong negative impact on health-related quality of life (HRQoL) including social, emotional, and physical functioning, and psychological burden (with greater symptoms of anxiety and depression) to patients and their families/caregivers. In addition, FA incurs a substantial socioeconomic burden owing to direct and indirect costs, not only to the patients and their families but also to the healthcare system, taxpayers and society. It is also worth observing that the total socioeconomic burden and total costs due to FA varies by region/country, and the kind of FA.[^10][^15][^16][^17]

Current management strategies for FA focus primarily on allergen avoidance and symptom management.[^12] Allergen avoidance is the simplest form of management but is often not successful over the long term due to accidental exposures.[^12][^18] A retrospective study in peanut-allergic children found accidental peanut ingestion rates of 14% per year.[^19] In a separate longitudinal observational study, approximately 12% of children with peanut allergy experienced adverse reactions from accidental peanut exposure despite best efforts at allergen avoidance.[^20] According to the European Academy of Allergy and Clinical Immunology (EAACI), recommendations for management of FA include the use of epinephrine/adrenaline in patients with risk of anaphylaxis and acute life-threatening symptoms while antihistamines may have value for the treatment of acute non-life-threatening symptoms.[^12]

Oral immunotherapy (OIT) has also been shown to be effective in the management of FA. OIT is based on the administration of increasing doses of the allergenic food until a maintenance dose is reached, at which point many patients continue regular ingestion to maintain desensitization to prevent reactions from accidental ingestions. However, OIT carries significant risks; allergic reactions to accidental food allergen exposure may not be completely eliminated and allergic reactions to maintenance dosing may occur, and long-term need for continued maintenance dosing in most is required to sustain desensitization.[^21][^22][^23] Palforzia, a therapeutic peanut allergen powder, is currently the only approved (United States Food and Drug Administration and European Medicines Agency approved[^24][^25]) OIT product and is used for the treatment of peanut allergy in children.[^21][^26] However, many patients are sensitized to multiple allergens, and would therefore require broader-spectrum OIT. Eosinophilic gastrointestinal (GI) disease and serious adverse reactions including anaphylaxis also need to be balanced with the potential benefits of OIT.[^27]
There is an urgent requirement to address the unmet needs of patients with FA, particularly of those with multiple FAs as they are more likely to experience accidental exposure and often need to avoid several food groups, which can lead to harmful effects on nutrition, growth, and quality of life (QoL). Ligelizumab is currently under investigation for the management of IgE-mediated FA. This article will provide the rationale for development of ligelizumab in FA based on its unique mechanistic characteristics and its existing efficacy and safety data in other therapeutic areas. In this context, this article will provide an overview of the central role of IgE in FA and the existing evidence for anti-IgE therapies in FA.

THE IG/E/FCεRI PATHWAY IS CONSIDERED A MAJOR DISEASE DRIVER IN FOOD ALLERGY

Initial allergen sensitization

The development of FA begins with a period of sensitization that may occur through multiple pathways, often including early cutaneous exposure to food protein through a compromised skin barrier. Langerhans cells in the epidermis may take up these food proteins and induce a type 2 helper T cell (Th2) response and IgE production by B cells. In addition, allergic foods ingested in the presence of damaged gut epithelia may also produce inflammatory cytokines—the so-called alarmins—that include interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin. These factors activate type 2 innate lymphoid cells, mast cells, and dendritic cells. In a pro-inflammatory cytokine environment, dendritic cells take up and process the antigen to smaller peptides for antigen presentation to naïve T cells via the major histocompatibility complex. This interaction occurs in tissues and lymph nodes and leads to the differentiation of naïve T cells into Th2 cells. These cells produce various cytokines, including IL-4, IL-5, and IL-13, thereby promoting gut infiltration of eosinophils and basophils leading to downstream target effects that promote allergic sensitization and inflammation. In addition, T cell-derived IL-4 and IL-13 drive isotype class switching and B-cell differentiation into plasma cells, producing food allergen-specific IgE antibodies—a process that can occur in classical lymphoid organs and locally in the GI tissues. IgE synthesized in the mucosa is transported through the epithelium into the gut lumen, where they capture allergens that are delivered back to the mucosa.

IgE binds via its fragment crystallizable (Fc) domain to its two major receptors, the high-affinity IgE receptor (FceRI) and the low-affinity IgE receptor (FceRII) or CD23 (hereafter always referred to as CD23). FceRI is mainly expressed on mast cells, basophils, dendritic cells, intestinal epithelium, and airway smooth muscle cells, whereas CD23 is found on B cells, monocytes, epithelial cells, airway smooth muscle cells, eosinophils, and platelets. Accordingly, allergens can elicit a wide variety of effects upon crosslinking of receptor-bound IgE depending on the receptor and cell type.

Secondary allergen challenge

Re-exposure to the allergen, most often through oral ingestion, leads to the crosslinking of FceRI-bound IgE on mast cells and basophils resulting in cell degranulation and release of vasoactive and pro-inflammatory mediators. This immediate hypersensitivity reaction plays an important role in the acute allergic response and is mediated by the release of preformed mediators such as histamine, tryptase, and chymase. In addition, allergen crosslinking of IgE/FceRI activates de novo synthesis of leukotrienes, prostaglandins, and platelet-activating factor that contribute to the characteristic symptoms of an allergic reaction and anaphylaxis. In addition, IgE may be involved in sustaining the type 2 immune response in several different ways. Allergen-induced crosslinking of IgE bound to FceRI on plasmacytoid dendritic cells (pDC) impairs the natural function of these cells to promote development of regulatory T cells. This process could contribute to unrestricted development of Th2 cell-biased immune response found in food-allergic patients. Furthermore, IgE/allergen complexes, via binding to FceRI or CD23, can promote antigen presentation by a variety of antigen-presenting cells with subsequent release of type 2 cytokines by polarized Th2 cells. IgE also increases the sensitivity of FceRI-expressing cells to IgE-mediated responses by stabilizing and thereby enhancing the expression of FceRI.
Finally, IgE can actively transport food allergens into the gut mucosa in the form of immune complexes via transcytosis through gut epithelial cells.\textsuperscript{48} [Fig. 1].

**EXISTING EVIDENCE FOR ANTI-IGE THERAPY IN FOOD ALLERGY**

As IgE plays a significant role in the pathology of FA, the investigation of an anti-IgE therapy for FA is well reasoned.\textsuperscript{50–63} TNX-901 (talizumab) was the first anti-IgE to be studied in the treatment of FA and was shown to protect most patients against allergic reactions from accidental peanut exposure by substantially increasing the peanut reaction threshold.\textsuperscript{50} Once-monthly subcutaneous talizumab 150–450 mg demonstrated a dose-dependent increase in the threshold of peanut to induce a clinical reaction. The efficacy of talizumab 450 mg was statistically significant vs placebo ($p < 0.001$), with subjects showing an average $\sim 16$-fold increase in their peanut reaction threshold.\textsuperscript{50} However, talizumab was not developed further in FA.

Omalizumab is the only monoclonal anti-IgE antibody approved for clinical use, currently for the treatment of severe allergic asthma, CSU, and severe nasal polyposis. It has also been investigated for the treatment of FA, both as monotherapy and in combination with OIT. Studies involving omalizumab have evaluated treatment for peanut, milk, and multi-food allergies, and all have produced encouraging results.\textsuperscript{51–54,64,65}

In an unblinded study, marked changes in peanut challenge thresholds were observed after only 1–3 doses of omalizumab.\textsuperscript{66} In a double-blind, placebo-controlled trial, in combination with milk OIT, long-term treatment with omalizumab helped reduce the number of dose-related adverse reactions of OIT. Following 28 months of treatment,
desensitization was seen in 88.9% of patients with omalizumab add-on treatment to OIT compared with 71.4% of patients with OIT alone ($p = 0.18$). Sustained unresponsiveness to oral food challenge by month 32 demonstrated that $\sim 48.0\%$ of patients maintained desensitization in the omalizumab add-on group vs $35.7\%$ in the placebo group ($p = 0.42$). Similar results were observed in a randomized, double-blind, placebo-controlled study that investigated the effect of omalizumab on sustained desensitization to peanut OIT. In a randomized, double-blind, placebo-controlled trial that investigated desensitization with multi-food OIT in combination with omalizumab, the combination of omalizumab and OIT significantly improved desensitization to multiple trigger foods in patients with multiple FAs, with a significantly greater proportion of patients passing the double-blind, placebo-controlled food challenge vs OIT only (83% vs 33%; $p = 0.004$). More recently, the effect of sustained unresponsiveness with omalizumab-facilitated multi-allergen OIT has been explored in a randomized, double-blind, placebo-controlled Phase 2 pilot trial. The results showed that sustained desensitization after omalizumab-facilitated multi-OIT is higher through continued maintenance OIT dosing of either 300 mg or 1 g of each food allergen as opposed to discontinuation of multi-allergen OIT (85% vs 55%, $p = 0.03$). Rates of sustained unresponsiveness following omalizumab-facilitated multi-OIT appeared higher than those achievable with OIT alone; however, larger studies are needed to explore this further. Omalizumab in FA is currently being investigated in an ongoing Phase 3 study (OUtMATCH: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants) (NCT03881696).

**NEXT GENERATION ANTI-IGE LIGELIZUMAB – KEY CHARACTERISTICS**

Ligelizumab, a derivative of talizumab, is a humanized immunoglobulin-G1 (IgG1/x) monoclonal antibody that binds to human IgE with $\sim 88\%$ fold higher affinity than omalizumab, as observed through *in vitro* laboratory investigation. Ligelizumab recognizes an epitope that spans across the Fc domain Ce3 regions of human IgE and thereby blocks IgE binding to FceRI and CD23. The epitope of ligelizumab on IgE is different from that recognized by omalizumab and shows greater overlap with the binding site of FcεRI compared with omalizumab (Fig. 2). The different epitopes recognized by the two anti-IgE antibodies translate into a qualitatively different IgE inhibition profile whereby ligelizumab inhibits the binding of free IgE to FcεRI more potently than omalizumab. Conversely, omalizumab is more potent in blocking the binding of IgE to CD23 than ligelizumab. Consequently, ligelizumab displays higher potency in the blocking of IgE/FcεRI signaling resulting in a strong reduction in the inflammatory mediator release from the mast cells (Fig. 3). In patients treated with ligelizumab, circulating IgE is rapidly neutralized and becomes inaccessible to IgE receptors, thereby blocking the crosslinking of receptor-bound IgE and its downstream effects as evidenced by inhibition of skin prick test responses. As already discussed, the IgE/FcεRI pathway is considered a major disease driver in FA; therefore, ligelizumab is viewed as a promising candidate molecule to be investigated in the management of patients with FA.

**AVAILABLE CLINICAL EVIDENCE ON THE EFFICACY OF LIGELIZUMAB IN ASTHMA AND CHRONIC SPONTANEOUS URTICARIA**

Details of completed and ongoing ligelizumab clinical trials in asthma and CSU are listed in Table 1.

Two Phase 2 clinical trials have investigated ligelizumab in allergic asthma following one Phase 1 trial in atopic subjects. In a Phase 1 trial, ligelizumab showed greater reduction in skin prick wheal allergic responses in atopic subjects compared with omalizumab (>95% vs 41%; $p < 0.001$). A dose-dependent reduction in circulating free IgE levels and basophil cell surface-bound IgE levels was also observed with ligelizumab. In addition, ligelizumab demonstrated a dose- and time-dependent reduction in basophil FceRI and IgE levels. In a Phase 2 trial in patients with mild allergic asthma, ligelizumab at a dose of up to 240 mg once every 2 weeks (Q2W) showed superior suppression of the skin prick test ($p = 0.002$ and $p < 0.0001$ for 72 mg and 240 mg, respectively) and a $\sim 3$-fold greater reduction in reactivity (bronchial airway allergen PC$_{15}$ response) to the allergen compared
with omalizumab (dosed as per the dosing table posology) at Week 12 (240 mg; \( p = 0.10 \)). However, a ligelizumab Phase 2 study in patients with severe allergic asthma did not achieve the primary endpoint of \( \geq 0.5 \)-point difference in Asthma Control Questionnaire-7 score to demonstrate superiority for ligelizumab vs placebo at Week 16. This asthma study provided first insights that ligelizumab and omalizumab may have different properties, which may result in different clinical outcomes in a highly complex disease such as asthma. Indeed, a subsequent pre-clinical study determined significant differences in molecular binding profile and functional modes-of-action of ligelizumab compared with omalizumab.

With regard to CSU, a Phase 2b study in adult patients demonstrated a dose-dependent response to ligelizumab with more patients achieving complete control of disease activity compared with omalizumab and placebo at Week 12 (weekly Hives Severity Score = 0 response rates at Week 12 were 30%, 51%, and 42% for ligelizumab 24, 72, and 240 mg, respectively, vs 26% for omalizumab [CSU dose 300 mg] and 0% for placebo). Patients who completed this Phase 2b study and presented with active disease entered into an open-label safety extension study (NCT02649218). The results showed that one-year treatment with ligelizumab 240 mg Q4W showed no newly identified or unexpected safety concerns. A Phase 2b study (NCT03437278) with adolescent patients with CSU has recently been completed. Ligelizumab received breakthrough designation from the US FDA for CSU and is currently in Phase 3 trials (NCT03580369, NCT03580356, NCT03907878, NCT04210843) for the treatment of CSU in adults and adolescent patients aged \( \geq 12 \) years. Combined, these studies recruited over 2000 patients to investigate the efficacy and safety of ligelizumab in patients with CSU inadequately controlled by H1-antihistamines. At the time of the interim analysis, the 2 identically designed Phase 3 studies (NCT03580369 and NCT03580356) met their primary endpoint of superiority vs placebo (change from baseline in weekly Urticaria Activity Score) at Week 12 in the treatment of CSU; however, superiority vs omalizumab was not demonstrated.
LIGELIZUMAB – EXISTING EVIDENCE ON SAFETY AND TOLERABILITY

In a Phase 1 study in patients with atopy, the most commonly reported adverse events (AEs) were headache and upper respiratory tract infection. Mild-to-moderate urticaria was reported as the most significant AE in this study, with an incidence of ~17% in any ligelizumab dose group; the event resolved spontaneously or with the use of antihistamines. Only 2 (5%) patients on ligelizumab discontinued due to AEs of asthma exacerbations and flu-like illness, but neither were considered to be related to the study drug. In the Phase 2/2b studies in patients with mild allergic asthma (NCT01703312), severe uncontrolled asthma (NCT01716754 [core study]), and CSU (NCT02075008 [extension study], and CSU (NCT02477332 [core

Fig. 3 Consequences of ligelizumab-mediated IgE binding blockade to FcεRI and CD23 expressing cells. Ligelizumab binds to free IgE and blocks its binding to FcεRI expressed on mast cells and basophils. The reduced availability of free IgE leads to the loss of FcεRI receptor numbers, which contributes to the effects of ligelizumab. The combined effects lead to a reduction in allergen-induced activation of mast cells and basophils, thereby reducing the release of pro-inflammatory mediators, with the potential to prevent food-induced allergic response and anaphylaxis. Ligelizumab also blocks the IgE/CD23 pathway, which may have implications for antigen presentation and IgE transport.

GI, gastrointestinal tract; FA, food allergy, FcεRI, high-affinity IgE receptor; CD23, low-affinity IgE receptor; IgE, immunoglobulin E
| NCT number  | Study Phase | Number of patients/planned/actual enrolment | Study population | Study description                                                                                                                                                                                                 | Recruitment Status (Study Start date–End date) |
|------------|-------------|---------------------------------------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| NCT01703312 | Phase 2     | 37                                          | Asthma           | Randomized, double-blind, placebo- and comparator-controlled study evaluating the effect of multiple doses of ligelizumab compared with omalizumab in asthma induced by allergen bronchial provocation                                                                 | Completed (Nov 2012–Oct 2013)                |
| NCT01716754 | Phase 2     | 471                                         | Asthma           | Multicenter, randomized, double-blind, placebo- and active-controlled study with exploratory dose-ranging to investigate the efficacy and safety of 16-week treatment with subcutaneous ligelizumab in asthma patients not adequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists | Completed (Dec 2012–Jan 2016)                |
| NCT02477332 | Phase 2b    | 382                                         | CSU              | Multicenter, randomized, double-blind, placebo- and active-controlled dose-finding study of ligelizumab as an add-on therapy to investigate the efficacy and safety in patients with CSU                                                                 | Completed (Jul 2015–Jun 2017)                |
| NCT number  | Study Phase | Number of patients/planned/actual enrolment | Study population | Study description                                                                                                                                                                                                 | Recruitment Status (Study Start date–End date)               |
|-------------|-------------|---------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| NCT02649218 | Phase 2     | 226                                         | CSU              | Open-label, multicenter, extension study to evaluate the long-term safety of ligelizumab 240 mg s.c. given every 4 weeks for 52 weeks in CSU patients who completed study NCT02477332                                                                  | Completed (May 2016-May 2019)                                |
| NCT03437278 | Phase 2b    | 49                                          | CSU              | Dose-finding, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of ligelizumab in adolescent patients with CSU                                                                 | Completed (Aug 2018-Feb 2021)                                |
| NCT03580369 | Phase 3     | 1072                                        | CSU              | Multicenter, randomized, double-blind, active- and placebo-controlled, parallel-group study to investigate the efficacy and safety of ligelizumab in the treatment of CSU in adolescents and adults inadequately controlled with H1-antihistamines | Completed (Oct 2018-Jun 2022)                                |
| NCT03580356 | Phase 3     | 1079                                        | CSU              | Multicenter, randomized, double-blind, active- and placebo-controlled, parallel-group study to investigate the efficacy and safety of                                                                                                                                   | Completed (Oct 2018-Jun 2022)                                |

(continued)
| NCT number     | Study Phase | Number of patients/planned/actual enrolment | Study population | Study description                                                                 | Recruitment Status (Study Start date–End date) |
|---------------|-------------|---------------------------------------------|------------------|-----------------------------------------------------------------------------------|-----------------------------------------------|
| NCT03907878   | Phase 3     | 66                                          | CSU              | Multicenter, open-label study to investigate the safety/tolerability and efficacy of ligelizumab in the treatment of adult Japanese patients with CSU inadequately controlled with H1-antihistamines | Completed (Apr 2019–Jan 2022)               |
| NCT04210843   | Phase 3     | 1038                                        | CSU              | Multicentre, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy, and monotherapy in CSU patients who completed previous studies of ligelizumab in CSU | Active – not recruiting (Apr 2020–Ongoing)   |
| NCT04513548   | Phase 1     | 11                                          | Part 1: Healthy subjects and CSU patients Part 2: Chronic urticaria patients (CSU, cholinergic urticaria or cold urticaria) | A two-part, randomized double-blind study to investigate the Mechanism of Action of ligElizumab treatment in patients with chronic uRticaria (MASTER) | Terminated (Company decision)               |

Table 1. (Continued) Completed and ongoing clinical trials of ligelizumab in asthma and CSU* CSU, chronic spontaneous urticaria; NCT, National Clinical Trial; s.c., subcutaneous. *Details of the studies including the recruitment status is as of August 2022 (https://clinicaltrials.gov/)
study]) and NCT02649218 [extension study]), the most common AEs (occurring in ≥10% of patients) reported in any ligelizumab group were nasopharyngitis, asthma, oropharyngeal pain, diarrhea, headache, injection site reaction, injection site erythema, nasal congestion, viral upper respiratory tract infection, urinary tract infection, and urticaria. No ligelizumab dose-response relationship was observed in the occurrence of these events. No patient with mild allergic asthma discontinued the study due to AEs, while a very small proportion of patients with CSU (~2%) on any ligelizumab dose discontinued due to AEs, which was similar to or fewer than those discontinuing in the omalizumab and placebo arms (2% and 5%, respectively). In general, across these Phase 1 and Phase 2 studies, a majority of the AEs were mild to moderate in severity and were not suspected to be related to the study drug, with the exception of mild-to-moderate injection-site reactions. Serious AEs were reported in the Phase 2b core and extension studies in patients with CSU and in the Phase 2 core (NCT01716754) and extension studies (NCT02075008) in patients with asthma. In CSU Phase 2b core study, 11 (4.3%) patients on any ligelizumab dose experienced serious AEs, which was similar to that observed in the omalizumab group (3 [4%]) and lower than that in the placebo group (4 [9%]). In the CSU Phase 2b extension study, overall, 26 treatment-emergent serious AEs were reported in a total of 15 patients (6.6%) on ligelizumab, of which only the event of hypersensitivity (one case; [0.4%]) was reported to be related to the study drug, and this event has been positively adjudicated as anaphylaxis. In the asthma core study (NCT01716754), 12 (5.0%) patients on any ligelizumab dose, 1 (0.8%) patient on omalizumab, and 5 (5.2%) patients on placebo group experienced serious AEs. Of these, the serious AE of drug hypersensitivity was noted in 1 (0.5%) patient on any ligelizumab dose group. In the asthma extension study (NCT02075008), overall, 19 serious AEs were reported in a total of 270 patients (7.0%) on ligelizumab, that included 1 serious AE (0.4%) of anaphylactic reaction and 1 serious AE (0.4%) of drug hypersensitivity. No clinically meaningful changes in hematology, blood chemistry, urinalysis, vital signs, and electrocardiographic recordings have been reported with ligelizumab. No deaths in ligelizumab treatment arms have been reported in any Phase 1 or Phase 2 studies. Overall, ligelizumab has been reported to be well tolerated with doses ranging from 12 mg once every 2 weeks (Q2W) to 240 mg Q2W.

**PROSPECT FOR LIGELIZUMAB IN FOOD ALLERGY**

In early Phase 1 trials, ligelizumab showed dose- and time-dependent suppression of allergen-elicited wheals with a standardized skin prick test. Given that the skin prick test is one of the recommended diagnostic tools for various allergic diseases such as FA, this effect of ligelizumab in reducing the skin prick wheal allergic response and free IgE levels may translate into beneficial effects in such diseases. Based on previous ligelizumab studies and extrapolation to patients with FA, modeling of the pharmacokinetic (PK)/pharmacodynamic (PD) basophil FceRI show that the selected dose regimens of 120 mg and 240 mg every 4 weeks (Q4W) may be most appropriate for the majority of patients with FA. The ongoing Phase 3 study of ligelizumab in FA is a randomized, double-blind, placebo-controlled, 52-week study assessing 2 dose regimens (120 mg and 240 mg administered subcutaneously Q4W) in patients aged 6–55 years with a confirmed diagnosis of peanut allergy (NCT04984876). The reason for selecting the same dose range for patients in different age groups is based on the fact that pediatric patients starting 6 years have higher baseline IgE levels than adults. As with omalizumab, dosing will be restricted in patients with elevated IgE levels with an upper limit of 2000 IU/mL in the planned Phase 3 trial, a study that will provide more clarity on the efficacy and safety of ligelizumab in patients with FA and provide guidance on the optimal posology.

**CONCLUSIONS**

Although the financial and psychosocial burden of FA is high, and the prevalence of FA in many countries is on the rise, existing treatment options for FA are extremely limited. Due to the important role played by IgE/FceRI pathway in FA, IgE suppression with monoclonal antibodies, such as talizumab and omalizumab, has been shown to provide clinical benefits in patients with FA. Allergen avoidance and patient nutrition care...
continues to be a key approach for food allergy management. In addition, anti-IgE therapy has the potential to complement the standard of care by diminishing the risk to the patient. Ligelizumab (a talizumab derivative), is a next generation humanized monoclonal antibody that shows greater overlap with the binding site of FceRI and binds to human IgE with ~88-fold higher affinity compared with omalizumab. Accordingly, ligelizumab has displayed high potency to block IgE/FceRI signaling in both in vitro and in vivo studies. Consequently, considering its potent suppression of both serum IgE and skin prick test, and known safety profile, ligelizumab is a promising candidate to be investigated in the management of patients with IgE-mediated FA.

**Abbreviations**

AE, adverse event; CSU, chronic spontaneous urticaria; EAACI, European Academy of Allergy and Clinical Immunology; FA, food allergy; Fc, fragment crystallizable; FceRI, high-affinity IgE receptor; FceRII, low-affinity IgE receptor; GI, gastrointestinal; HRQoL, health-related quality of life; IgE, immunoglobulin E; IL, interleukin; OIT, oral immunotherapy; PD, pharmacodynamic; pDC, plasmacytoid dendritic cells; PK, pharmacokinetic; Q2W, once every 2 weeks; Q4W, once every 4 weeks; QoL, quality of life; Th1, type 1 helper T cell; Th2, type 2 helper T cell.

**Acknowledgments**

The authors thank Mohammad Fahad Haroon (PhD), Sahaja Banda, and Anupama Boddupalli of Novartis Healthcare, Hyderabad, India, for providing medical writing support which was funded by Novartis Pharma AG, Switzerland in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

**Funding**

Not applicable.

**Author contributions**

All authors made substantial contributions to the conception and design of this article; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval for the version to be published; and agree to be accountable for all aspects of the work.

**Ethics approval**

Not applicable.

**Submission declaration**

This manuscript is being submitted only to *World Allergy Organization Journal* and has not been previously submitted to another journal, nor is it currently under consideration by another journal.

**Consent for publication**

The authors’ consented to the publication of this review.

**Declaration of competing interest**

**Robert A Wood** receives research support from NIAID, Aimmune, Astellas, DBV, FARE, Genentech, HAL-Allergy, Novartis, and Regeneron.

**R. Sharon Chinthrajah** reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, FARE, and MCHRI; is an advisory member for Alladapt Therapeutics, Genentech, Allergenis, Novartis, Sanofi, and Nutricia; and received personal fees from Before Brands, all outside the submitted work.

**Alexander Eggel** reports consulting activities for Novartis and received research and travel grant support from Novartis.

**Ivan Bottoli, Paolo Tassinari, Aurelie Gautier, and Maximilian Woisetschlaeger** are employees of Novartis Pharma AG, Basel, Switzerland.

**Pablo Altman** is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States.

**Author details**

aDivision of Allergy & Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. bSean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.

cDepartment of BioMedical Research, University of Bern, Bern, Switzerland. dDepartment of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland. eNovartis Pharma AG, Basel, Switzerland. fNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

**REFERENCES**

1. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. *J Allergy Clin Immunol.* 2018;141(1):41–58.

2. Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. *Nat Rev Immunol.* 2016;16(12):751–765.

3. Mahdavinia M. Food allergy in adults: presentations, evaluation, and treatment. *Med Clin North Am.* 2020;104(1):145–155.

4. Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. *JAMA Netw Open.* 2019;2(1), e185630.

5. Warren CM, Jiang J, Gupta RS. Epidemiology and burden of food allergy. *Curr Allergy Asthma Rep.* 2020;20(2):6.

6. Koplin JJ, Mills EN, Allen KJ. Epidemiology of food allergy and food-induced anaphylaxis: is there really a western world epidemic? *Curr Opin Allergy Clin Immunol.* 2015;15(5):409–416.

7. Loh W, Tang MLK. The epidemiology of food allergy in the global context. *Int J Environ Res Public Health.* 2018;15(9):2043.

8. Zellweger F, Eggel A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. *Allergy.* 2016;71(12):1652–1661.
9. Bachert C, Maurer M, Palomares O, Busse WW. What is the contribution of IgE to nasal polyposis? J Allergy Clin Immunol. 2021;147(6):1997-2008.

10. Anvari S, Miller J, Yeh CY, Davis CM. IgE-mediated food allergy. Clin Rev Allergy Immunol. 2019;57(2):244-260.

11. NIAID-Sponsored Expert Panel, Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1-S58.

12. Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69(8):1008-1025.

13. Kearsey I, Yik YI, Southwell BR, Hutson JM. Constipation: a symptom of chronic food intolerance? In: Dietary Interventions in Gastrointestinal Diseases: Foods, Nutrients and Dietary Supplements. 2019:63-72. https://doi.org/10.1016/B978-0-12-814468-8.00005-3.

14. Messina M, Venter C. Recent surveys on food allergy prevalence. Nutr Today. 2020;55(1):22-29.

15. Golding MA, Gunnarsson NV, Middelveld R, Ahlstedt S, Protudjer JLP. A scoping review of the caregiver burden of pediatric food allergy. Ann Allergy Asthma Immunol. 2021;127(5):536-547. e3.

16. Fong AT, Ahlstedt S, Golding MA, Protudjer JLP. The economic burden of food allergy: what we know and what we need to learn. Curr Treat Options Allergy. 2022;28:1-18.

17. Golding MA, Batac ALR, Gunnarsson NV, Ahlstedt S, Middelveld R, Protudjer JLP. The burden of food allergy on children and teens: a systematic review. Pediatr Allergy Immunol. 2022;33(3), e13743.

18. Giovannini M, D’Auria E, Caffarello C, et al. Nutritional management and follow up of infants and children with food allergy: Italian society of pediatric nutrition/Italian society of pediatric allergy and Immunology task force position statement. Ital J Pediatr. 2014;40:1.

19. Yu JW, Kagan R, Verreault N, et al. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol. 2006;118(2):466-472.

20. Cherkaoui S, Ben-Shoshan M, Alizadehfar R, et al. Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy. Clin Transl Allergy. 2015;5:16.

21. PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991-2001.

22. Anagnostou A. Weighing the benefits and risks of oral immunotherapy in clinical practice. Allergy Asthma Proc. 2021;42(1):118-123.

23. Chinthrajah RS, Purinton N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394(10207):1437-1449.

24. Palforzia Package Insert - US Food and Drug Administration; 2020. https://www.fda.gov/media/134838/download. Accessed November 24, 2021.

25. Palforzia Summary of Product Characteristics - European Medicines Agency; 2020. https://www.ema.europa.eu/en/documents/product-information/palforzia-epar-product-information_en.pdf. Accessed November 24, 2021.

26. Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mösges R. Optimum treatment strategies for polyallergic patients — analysis of a large observational trial. Curr Med Res Opin. 2015;31(12):2249-2259.

27. Patrawala M, Shih J, Lee G, Vickery B. Peanut oral immunotherapy: a current perspective. Curr Allergy Asthma Rep. 2020;20(5):14.

28. Wang J. Management of the patient with multiple food allergies. Curr Allergy Asthma Rep. 2010;10(4):271-277.

29. du Toit G, Tsakok T, Lack S, Lack G. Prevention of food allergy. J Allergy Clin Immunol. 2016;137(4):998-1010.

30. Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;121(6):1331-1336.

31. Hoh RA, Joshi SA, Lee JY, et al. Origins and clonal convergence of gastrointestinal IgE(+) B cells in human peanut allergy. Sci Immunol. 2020;5(45), eaay4209.

32. Oettgen HC, Burton OT. IgE receptor signaling in food allergy pathogenesis. Curr Opin Immunol. 2015;36:109-114.

33. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol. 2006;117(2):391-397.

34. Untersmayer E, Bises G, Starkl P, et al. The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells. PLoS One. 2010;5(2), e9023.

35. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454.

36. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature. 2000;406(6793):259-266.

37. Youssef LA, Schuyler M, Wilson BS, Oliver JM. Roles for the high affinity IgE receptor, FcεRI, of human basophils in the pathogenesis and therapy of allergic asthma: disease promotion, protection or both? Open Allergy J. 2010;3:91-101.

38. Chen XJ, Lycke N, Enerbäck L. Surface and gene expression of immunoglobulin E receptors on mast cells and mast-cell numbers in interleukin-4-gene knockout mice. Immunology. 1999;96(4):544-550.

39. López-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3(+)+Tregs. Eur Respir J. 2021;57(1), 2000751.

40. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8(4):310-315.

41. Maurer D, Fiebig S, Ebner C, et al. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol. 1996;157(2):607-616.

42. Mudde GC, Van Reijisen FC, Boland GJ, de Gast GC, Bruijnzeel PL, Bruijnzeel-Koomen CA. Allergen presentation by
epidermal Langerhans’ cells from patients with atopic dermatitis is mediated by IgE. *Immunology.* 1990;69(3):335-341.

43. Sharquie IK, Al-Ghouleh A, Fitton P, Clark MR, Armour KL, Sewell HF. An investigation into IgE-facilitated allergen recognition and presentation by human dendritic cells. *BMC Immunol.* 2013;14:54.

44. Villazala-Merino S, Rodriguez-Dominguez A, Stanek V, et al. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. *J Allergy Clin Immunol.* 2020;145(3):958–967.e5.

45. Cianferoni A. Non-IgE mediated food allergy. *Curr Pediatr Rev.* 2020;16(2):95–105.

46. MacGlashan Jr D, McKenzie-White J, Chichester K, et al. In vitro regulation of FcεRIα expression on human basophils by IgE antibody. *Blood.* 1998;91(5):1633–1643.

47. Yamaguchi M, Lantz CS, Oettgen HC, et al. IgE enhances mouse mast cell Fc(ε)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. *J Exp Med.* 1997;185(4):663–672.

48. Tu Y, Salim S, Bourgeois J, et al. CD23-mediated IgE transport across human intestinal epithelium: inhibition by blocking sites of translation or binding. *Gastroenterology.* 2005;129(3):928–940.

49. Lee JB. Regulation of IgE-mediated food allergy by IL-9 producing mucosal mast cells and type 2 innate lymphoid cells. *Immune Netw.* 2016;16(4):211–218.

50. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. *N Engl J Med.* 2003;348(11):986–993.

51. Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. *Eur J Pediatr.* 2011;170(11):1471–1474.

52. Rafi A, Do LT, Katz R, Shinkopf LE, Simons CW, Klaustrermeyer W. Effects of omalizumab in patients with food allergy. *Allergy Asthma Proc.* 2010;31(1):76–83.

53. Fiochi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. *J Allergy Clin Immunol Pract.* 2019;7(6):1901, 09.e5.

54. Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. *J Allergy Clin Immunol.* 2011;127(5):1309, 13010.e1.

55. Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab. *Allergy.* 2021;76(9):2809–2826.

56. Long A, Borro M, Sampath V, Chinthrajah RS. New developments in non-allergen-specific therapy for the treatment of food allergy. *Curr Allergy Asthma Rep.* 2020;20(1):3.

57. Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. *J Allergy Clin Immunol.* 2016;137(4):1103–1110.e11.

58. Frischmeyer-Guerrero PA, Masilamani M, Gu W, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. *J Allergy Clin Immunol.* 2017;140(4):1043–1053. e8.

59. MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. *J Allergy Clin Immunol.* 2017;139(3):873–881. e8.

60. Andorf S, Manohar M, Dominguez T, et al. Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab. *Allergy Asthma Clin Immunol.* 2017;13:51.

61. Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. *Lancet Gastroenterol Hepatol.* 2018;3(2):85–94.

62. Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. *ECLinicalMedicine.* 2019;7:27-38.

63. Suárez-Fariñas M, Suprun M, Chang HL, et al. Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles. *J Allergy Clin Immunol.* 2019;143(3):1038–1046.

64. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol.* 2020;146(3):595–605.

65. XOLAIR® (Omalizumab) Prescribing Information. https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed 05 Sep 2021.

66. Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. *J Allergy Clin Immunol.* 2012;130(5):1123–11229.e2.

67. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. *Nat Commun.* 2020;11(1):165.

68. Guntern P, Eggel A. Past, present, and future of anti-IgE biologics. *Allergy.* 2020;75(10):2491–2502.

69. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. *Clin Exp Allergy.* 2014;44(11):1371–1385.

70. Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. *J Allergy Clin Immunol.* 2016;138(4):1051–1059.

71. Renz H, Allen KJ, Sicherer SH, et al. Food allergy. *Nat Rev Dis Prim.* 2018;4, 17098.

72. Palaniyandi S, Liu X, Periasamy S, et al. Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation. *Mucosal Immunol.* 2015;8(6):1274–1284.

73. Selb R, Eckl-Dorna J, Neunkirchner A, et al. CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. *J Allergy Clin Immunol.* 2017;139(1):290, 299 e4.
74. Trischler J, Bottoli I, Janocha R, et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clin Transl Immunology. 2021;10(3):e1255.

75. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321-1332.

76. Novartis Press release. Novartis Provides an Update on Phase III Ligelizumab (QGE031) Studies in Chronic Spontaneous Urticaria (CSU). https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-ligelizumab-qge031-studies-chronic-spontaneous-urticaria-csu. Accessed 11 Jan 2022.

77. Maurer M, Giménez-Arnau A, Bernstein JA, et al. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study. Allergy. 2021. https://doi.org/10.1111/all.15175. Epub ahead of print.

78. Oriel RC, Wang J. Diagnosis and management of food allergy. Immunol Allergy Clin. 2021;41(4):571-585.

79. Lowe PJ, Bottoli I, Arm J, Skerjanec A, Groenewegen A, Maahs S. A PKPD mathematical model to determine efficacy of multiple doses of QGE031 (ligelizumab) vs. omalizumab and placebo in inhibiting skin responses in atopic asthmatics. Eur Respir J. 2015;46(59). https://doi.org/10.1183/13993003.congress-2015.PA5092.

80. Sacco C, Perna S, Vicari D, et al. Growth curves of "normal" serum total IgE levels throughout childhood: a quantile analysis in a birth cohort. Pediatr Allergy Immunol. 2017;28(6):525-534.